title: Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
authors.forename: Hugues
authors.initials: H
authors.lastname: de Lavallade
authors.forename: Sinthiya
authors.initials: S
authors.lastname: Punnialingam
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
authors.forename: Marco
authors.initials: M
authors.lastname: Bua
authors.forename: Jamshid S
authors.initials: JS
authors.lastname: Khorashad
authors.forename: Ian H
authors.initials: IH
authors.lastname: Gabriel
authors.forename: Aristeidis
authors.initials: A
authors.lastname: Chaidos
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarria
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: David
authors.initials: D
authors.lastname: Marin
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D000069439:Dasatinib; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000139:chemically induced*; D011743:Pyrimidines / Q000009:adverse effects*; D012189:Retrospective Studies; D013844:Thiazoles / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib